The Q3 sales exceeded the consensus expectations and the healthy growth was supported by both segments. Consequently, the management revised its full-year sales and profitability guidance upwards to which the market’s reaction was ebullient with the share price ending the day 11% higher. Overall, the promising long-term prospects for the animal healthcare market, along with the firm’s strong R&D focus and robust balance sheet, support our positive stance on Virbac.